Strain Profile
Save

Bifidobacterium infantis R0033

◔ Human-origin
Sequenced
Public genome assembly available

Bifidobacterium infantis R0033 is a strain studied primarily in infant populations, where it has been evaluated in several randomized controlled trials alongside other probiotic strains. Human trials have examined secretory immunoglobulin A (sIgA) levels, an antibody important for mucosal immune defense, in formula-fed infants. Pilot RCT data have also examined gut microbiota composition and digestive comfort in early life. Most evidence comes from multi-strain formulations, making it difficult to isolate this strain's specific contribution; adult data are currently limited. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.

Where it's been studied

Share of this strain's 6 body-system-tagged papers that concern each system. Research coverage, not measured effect.

Gut 6 papers · 100%
Immune 4 papers · 67%
Respiratory 2 papers · 33%
Skin 1 paper · 17%

Symptoms in the research

Share of this strain's 2 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.

Diarrhea 2 papers · 100%
Eczema / Atopic dermatitis 1 paper · 50%
Respiratory infections 1 paper · 50%

Research

9 papers reference this strain in the probiotic database.

Match confidence
2022 IN_VITRO
Human milk oligosaccharide-sharing by a consortium of infant derived Bifidobacterium species
· Scientific Reports
 2018 RCT
Modulatory effect of three probiotic strains on infants’ gut microbial composition and immunological parameters on a placebo-controlled, double-blind, randomised study
· Beneficial Microbes
 2017 RCT
Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial
· Beneficial Microbes
 2026 RCT
Precision synbiotic intervention with 2′-fucosyllactose and infant-derived Bifidobacterium modulates gut-immune axis and reduces disease risk in toddlers: a randomized controlled trial
· Frontiers in Nutrition
 2019 RCT
Probiotics maintain intestinal secretory immunoglobulin A levels in healthy formula-fed infants: a randomised, double-blind, placebo-controlled study
· Beneficial Microbes
 2017 RCT
Effect of probiotics on digestibility and immunity in infants
· Medicine
 2010 OBSERVATIONAL
Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study
· Therapeutic Advances in Respiratory Disease
 2016 RCT
Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial
· Beneficial Microbes
 2009 IN_VITRO
Preliminary screening of Bifidobacteria spp. and Pediococcus acidilactici in a Swiss cheese curd slurry model system: Impact on microbial viability and flavor characteristics
· International Dairy Journal
Browse all 9 papers →

Discussion

Be the first to comment.

Sign in to join the discussion.

No comments yet.

Citations

Selected papers that name this strain.

  1. [1]
    Precision synbiotic intervention with 2′-fucosyllactose and infant-derived Bifidobacterium modulates gut-immune axis and reduces disease risk in toddlers: a randomized controlled trial
    · Frontiers in Nutrition · 2026
    PMID 42598364 →
  2. [2]
    Modulatory effect of three probiotic strains on infants’ gut microbial composition and immunological parameters on a placebo-controlled, double-blind, randomised study
    · Beneficial Microbes · 2018
    PMID 29726280 →
  3. [3]
    Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial
    · Beneficial Microbes · 2017
    PMID 28555502 →